Vonoprazan free base | CAS#881681-00-1 | (P-CAB

MedKoo Cat#: 526560 | Name: Vonoprazan free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vonoprazan (TAK-438) is a highly potent, orally administered potassium-competitive acid blocker (P-CAB) that directly and reversibly inhibits gastric H⁺/K⁺-ATPase, with an in vitro IC₅₀ of approximately 17–19 nM. It produces a rapid, sustained elevation of intragastric pH, maintaining pH ≥ 4 for over 85–90% of a 24-hour period following a single dose. Unlike conventional proton pump inhibitors (PPIs), vonoprazan does not require acid-mediated activation, exhibits a faster onset of action, and demonstrates low interindividual variability, including minimal influence by CYP2C19 polymorphisms. Its pharmacodynamic profile supports clinical use in gastroesophageal reflux disease (GERD), peptic ulcers, and Helicobacter pylori eradication regimens where more potent and consistent acid suppression is critical.

Chemical Structure

Vonoprazan free base

CAS#881681-00-1 (free base)

Theoretical Analysis

MedKoo Cat#: 526560

Name: Vonoprazan free base

CAS#: 881681-00-1 (free base)

Chemical Formula: C17H16FN3O2S

Exact Mass: 345.0947

Molecular Weight: 345.39

Elemental Analysis: C, 59.12; H, 4.67; F, 5.50; N, 12.17; O, 9.26; S, 9.28

Price and Availability

Size	Price	Availability
100mg	USD 90.00	Ready to ship
250mg	USD 150.00	Ready to ship
500mg	USD 250.00	2 Weeks
1g	USD 450.00	2 Weeks
2g	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

881681-00-1 (free base) 1260141-27-2 (fumarate) 881681-01-2 (fumarate)

Synonym

Vonoprazan; TAK-438; TAK 438; TAK438

IUPAC/Chemical Name

1-(5-(2-Fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine

InChi Key

BFDBKMOZYNOTPK-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3

SMILES Code

CNCC1=CN(S(=O)(C2=CC=CN=C2)=O)C(C3=CC=CC=C3F)=C1

Appearance

Solid powder

Purity

>97% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA:Vonoprazan free base current batch, Lot#C25B04B25

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 345.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shih CA, Wu DC, Shie CB, Hsu PI. Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review. Microorganisms. 2025 Mar 21;13(4):715. doi: 10.3390/microorganisms13040715. PMID: 40284552; PMCID: PMC12029877. 2: Sun X, Li D, Cui L, Du S, Wang X, Wu N. Rabeprazole- and vonoprazan-based dual therapies for H pylori eradication: effective with low side effects, rabeprazole being more cost-effective. Am J Transl Res. 2025 Mar 15;17(3):2067-2075. doi: 10.62347/EWFJ6972. PMID: 40226000; PMCID: PMC11982854. 3: Zhang MM, Wang MD, Yang SY, Hu JQ, Zhu BQ, Wei YK, Zhang CL, Long EW. The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis. J Infect Public Health. 2025 Apr 8;18(7):102768. doi: 10.1016/j.jiph.2025.102768. Epub ahead of print. PMID: 40220504. 4: Parmar MS, Shah DA, Chhalotiya UK. Stability indicating HPTLC - densitometric method for estimation of vonoprazan fumarate. Drug Dev Ind Pharm. 2025 Apr 12:1-9. doi: 10.1080/03639045.2025.2492192. Epub ahead of print. PMID: 40208797. 5: Dong Y, Duan Z, Liu M, Ding Y, Chen G, Wang R, Xu X, Ding L, Zhan Q, Pan C, Li H, Yang F, Dai X, Li X, Wu X, Peng P, Wang J, Hu K, Hu D, Jie Q, Zhang Z. Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of Helicobacter pylori infection with vonoprazan amoxicillin: a prospective, multicenter, randomized controlled trial. Front Pharmacol. 2025 Mar 24;16:1543352. doi: 10.3389/fphar.2025.1543352. PMID: 40196374; PMCID: PMC11973372. 6: Chen Y, Pan M, Yan K, Chen L, Li Z, Yu G, Zhang Q, Dai X. Efficacy and eradication effect of vonoprazan and high-dose amoxicillin dual therapy in CagA+VacA+Helicobacter pylori infected patients. Curr Med Res Opin. 2025 Mar;41(3):535-542. doi: 10.1080/03007995.2025.2479791. Epub 2025 Apr 7. PMID: 40181762. 7: Li X, Jiang C, Su Y, Gao R, Yang P, Qin Y, Zou Y, Liang W, Quan J, Pan L. Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth- containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis. Front Microbiol. 2025 Mar 19;16:1561749. doi: 10.3389/fmicb.2025.1561749. PMID: 40177490; PMCID: PMC11962034. 8: Kodama A, Komai M, Imai T, Nagaike K, Katsuura M. [Clinical Impact of Vonoprazan on the Use of Midazolam during Upper Gastrointestinal Endoscopy]. Yakugaku Zasshi. 2025;145(4):359-364. Japanese. doi: 10.1248/yakushi.24-00196. PMID: 40175151. 9: Abe H, Tarasawa K, Hatta W, Tanno N, Hatayama Y, Ogata Y, Saito M, Jin X, Koike T, Imatani A, Hamada S, Fujimori K, Fushimi K, Masamune A. Which of Vonoprazan Alone or Intravenous Proton Pump Inhibitor Followed by Vonoprazan Is Optimal for Reducing Delayed Bleeding in Gastric Endoscopic Submucosal Dissection? Digestion. 2025 Mar 25:1-10. doi: 10.1159/000545253. Epub ahead of print. PMID: 40132569. 10: Zhou K, Song Z. Eradication efficacy and the effect of vonoprazan- amoxicillin dual therapy on gut microbiota and antibiotic resistome. Lancet Microbe. 2025 Mar 13:101116. doi: 10.1016/j.lanmic.2025.101116. Epub ahead of print. PMID: 40090338. 11: Abraham P, Choudhuri G, Deshmukh S, Kak M, Tiwaskar M, Kochhar R, Sinha SK, Panigrahi SC, Shandil R, Khanna M, Garg R, Lamba GS, Jain M, Poddar P, Mishra A, Shah A, Kantharia C, Shah H, Saha I, Vazifdar K, Jain L, Borse N, Garg P, Kumar M, Sahu M, Nath P, Singh R, Sahu V, Bandyopadhyay S, Jaiswal S, Patil D, Bodas S, Vaghasia S, Khanna S, Swami OC, Chakravarty S, Murthy KV, Kumar V. Vonoprazan in Management of Refractory Gastroesophageal Reflux Disease: An Indian Expert Group Consensus Statements. J Assoc Physicians India. 2025 Mar;73(3):e29-e36. doi: 10.59556/japi.73.0878. PMID: 40087940. 12: Yan T, Wang J, Zhu R, Ma D, Gao J, Wang J, Chen Y, Sun K, Gu Q, Li L. Vonoprazan improves the efficacy of bismuth quadruple therapy containing doxycycline and metronidazole as first-line Helicobacter pylori treatment in penicillin-allergic patients: a randomized controlled trial. J Antimicrob Chemother. 2025 Apr 2;80(4):927-934. doi: 10.1093/jac/dkae467. PMID: 40048654. 13: Ojima KI, Imaizumi R, Komori T, Nishikawa T, Doi N, Nishiguchi S. Development of a Synthetic Route to Vonoprazan via Atom Transfer Radical Cyclization. J Org Chem. 2025 Mar 7;90(9):3485-3488. doi: 10.1021/acs.joc.4c02368. Epub 2025 Feb 26. PMID: 40009059; PMCID: PMC11894647. 14: Liu YX, Liu HN, Liu HQ, Yang YY, Cui HL, Fan LL, Sun WJ, Mei H, Wang XW, Yan G, Lan CH. Vonoprazan-Amoxicillin Dual Therapy Versus Drug Sensitivity-Based Individualized Therapy as a Rescue Regimen for Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter. 2025 Jan- Feb;30(1):e70009. doi: 10.1111/hel.70009. PMID: 39996433. 15: Taniguchi O, Saito Y, Yamaguchi Y, Sakai M, Ikezawa Y, Sakakibara-Konishi J, Eguchi M, Takekuma Y, Sugawara M. Severe Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan. Case Rep Oncol. 2025 Jan 3;18(1):151-158. doi: 10.1159/000542906. PMID: 39980523; PMCID: PMC11779124. 16: Song Z, Du Q, Zhang G, Zhang Z, Liu F, Lu N, Gu L, Kuroda S, Zhou L. Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double- blind, randomized, phase 3 study. Chin Med J (Engl). 2025 Feb 18. doi: 10.1097/CM9.0000000000003437. Epub ahead of print. PMID: 39965795. 17: Upadhyay R, Soni NK, Vora A, Saraf A, Haldipur D, Mukherjee D, Das D, Tiwaskar M, Nadkar M, Arun N, Kumar RB, Bhadade R, Rai RR, Bhargava S, Parikh S, Shetty S, Kant S, Jalihal U, Prasad VGM, Kotamkar A, Pallewar S, Qamra A. Association of Physicians of India Consensus Recommendations for Vonoprazan in Management of Acid Peptic Disorders. J Assoc Physicians India. 2025 Feb;73(2):68-77. doi: 10.59556/japi.73.0844. PMID: 39928002. 18: Jin T, Wu W, Zhang L, Xuan H, Zhang H, Zhong L. The efficacy and safety of Vonoprazan and Tegoprazan in Helicobacter pylori eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials. Therap Adv Gastroenterol. 2025 Jan 31;18:17562848251314801. doi: 10.1177/17562848251314801. PMID: 39898357; PMCID: PMC11783504. 19: Graham DY. Regarding the AGA Clinical Practice Update on Integrating Vonoprazan Into Clinical Practice. Gastroenterology. 2025 Apr;168(4):848-849. doi: 10.1053/j.gastro.2024.12.022. Epub 2025 Jan 20. PMID: 39848604. 20: Aschenbrenner DS. Vonoprazan approved for nonerosive esophagitis. Am J Nurs. 2025 Feb 1;125(2):19-20. doi: 10.1097/01.NAJ.0001098232.78894.18. Epub 2025 Jan 23. PMID: 39844226.